Last checked at 12 May 2020 07:00
IXICO plc
("IXICO" or the "Company")
Notice of Results
IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces it will release its interim results for the six months ended 31 March 2020 on Wednesday 20 May 2020.
A recording of the results presentation will be made available on the Company's website on the morning here: https://ixico.com/investors/company-information/investor-videos/
For further information please contact:
IXICO plc | +44 (0)20 3763 7498 | |
Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer |
| |
|
| |
Cenkos Securities PLC (Nominated adviser and sole broker) | +44 (0)20 7397 8900 | |
Giles Balleny / Max Gould (Corporate Finance) |
| |
Michael F Johnson / Russell Kerr (Sales) |
| |
|
| |
Walbrook PR Ltd | Tel: 020 7933 8780 or IXICO@walbrookpr.com | |
Paul McManus / Lianne Cawthorne / Alice Woodings | Mob: 07980 541 893 / 07584 391 303 / 07407 804 654 | |
|
| |
About IXICO
IXICO's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience.
Our goal is to be a leading proponent in the use of AI in clinical development, to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare. Through the deployment of novel AI algorithms, we analyse and interpret brain scans and digital biosensor data to enable better trial design, patient selection and ultimately clinical outcomes across all phases of clinical evaluation. Our data analytics services are deployed on some of the most important clinical trials in neuroscience, providing valuable insights to disease progression and patient safety, enabling our clients to make better informed decisions earlier in the clinical development pathway.
More information is available on www.IXICO.com